The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

Clinical trial NCT01962207 · COMPLETED

Trial details

NCT number: NCT01962207
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Infections, Meningococcal

Start date: 2013-10-01
Primary completion: 2017-12-01
Enrollment: 243

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.